This company is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
AVROBIO Croissance future
Future contrôle des critères 0/6
AVROBIO's earnings are forecast to decline at 18.4% per annum. EPS is expected to decline by 18% per annum.
Informations clés
-18.4%
Taux de croissance des bénéfices
-18.0%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 28.5% |
Taux de croissance des recettes | n/a |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 04 Jun 2024 |
Mises à jour récentes de la croissance future
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | N/A | -2 | N/A | N/A | 1 |
12/31/2025 | N/A | -7 | N/A | N/A | 1 |
12/31/2024 | N/A | -21 | N/A | N/A | 1 |
3/31/2024 | N/A | 30 | -50 | -50 | N/A |
12/31/2023 | N/A | 12 | -63 | -63 | N/A |
9/30/2023 | N/A | -4 | -79 | -79 | N/A |
6/30/2023 | N/A | -5 | -75 | -75 | N/A |
3/31/2023 | N/A | -101 | -90 | -89 | N/A |
12/31/2022 | N/A | -106 | -97 | -97 | N/A |
9/30/2022 | N/A | -109 | -101 | -99 | N/A |
6/30/2022 | N/A | -119 | -109 | -108 | N/A |
3/31/2022 | N/A | -122 | -101 | -99 | N/A |
12/31/2021 | N/A | -119 | -100 | -98 | N/A |
9/30/2021 | N/A | -119 | -104 | -103 | N/A |
6/30/2021 | N/A | -123 | -104 | -103 | N/A |
3/31/2021 | N/A | -121 | -104 | -104 | N/A |
12/31/2020 | N/A | -120 | -100 | -99 | N/A |
9/30/2020 | N/A | -114 | -89 | -87 | N/A |
6/30/2020 | N/A | -95 | -77 | -75 | N/A |
3/31/2020 | N/A | -82 | -74 | -72 | N/A |
12/31/2019 | N/A | -73 | -69 | -68 | N/A |
9/30/2019 | N/A | -66 | -62 | -61 | N/A |
6/30/2019 | N/A | -61 | -61 | -59 | N/A |
3/31/2019 | N/A | -55 | -51 | -49 | N/A |
12/31/2018 | N/A | -49 | -39 | -38 | N/A |
9/30/2018 | N/A | -40 | -36 | -35 | N/A |
6/30/2018 | N/A | -35 | -27 | -26 | N/A |
3/31/2018 | N/A | -27 | -21 | -20 | N/A |
12/31/2017 | N/A | -19 | N/A | -16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: AVRO's earnings are forecast to decline over the next 3 years (-18.4% per year).
Bénéfices vs marché: AVRO's earnings are forecast to decline over the next 3 years (-18.4% per year).
Croissance élevée des bénéfices: AVRO's earnings are forecast to decline over the next 3 years.
Chiffre d'affaires vs marché: Insufficient data to determine if AVRO's revenue is forecast to grow faster than the US market.
Croissance élevée des revenus: AVRO is forecast to have no revenue next year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if AVRO's Return on Equity is forecast to be high in 3 years time